丸在女性:重新审视安全性和临床结果
Diogo Pinto da Costa Viana1,2,3, Leonardo Jacobsen2, Luiz Henrique Gabriel2
1Department of Gynecology, Paulista School of Medicine, Federal University of São Paulo, São Paulo, BRA.
Cureus
|October 15, 2025
概括
皮下丸可为更年期妇女提供持续释放,但具有超生理学峰值和可变剂量. 对益处的证据有限,安全性需要通过随机试验进一步调查.
科学领域:
- 内分泌学 在内分泌学.
- 妇女健康 妇女健康
- 药理学 药理学是指药理学的学科.
背景情况:
- 在女性中的作用是有争议的,目前的指导方针限制了其使用.
- 皮下丸激素在标签之外使用,尽管对其药理动力学,疗效和安全性存在担忧.
研究的目的:
- 批判性地评估皮下丸丸的药理动力学,临床疗效和安全性,在近期和绝经后的妇女.
主要方法:
- 从1980年1月到2025年8月,PubMed/MEDLINE的结构化叙事审查.
- 包括原始的药理动力学或临床研究报告的丸在女性.
- 由于研究设计和结果的异质性,使用叙事综合.
主要成果:
- 颗粒提供持续释放 (4-6个月),但具有超生理学早期峰值和高可变性.
- 有限的证据表明,对性功能,情绪和骨密度的潜在益处主要来自观察性研究.
- 安全数据显示温和的雄激素作用;心血管,代谢和子宫内膜数据稀少.
结论:
- 皮下丸提供长期的输送,但具有药理动力学挑战,并依赖有限的证据.
- 报告的好处是产生假设的,安全性尚未得到证实.
- 建议在强大的随机试验之前进行个性化,非标签的使用和监测.
相关概念视频
Testosterone: Functions and Regulation
2.0K
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.0K
Menopause
3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K


